Literature DB >> 25425689

Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Uta Oelschlaegel1, Theresia M Westers2, Brigitte Mohr1, Michael Kramer1, Stefani Parmentier1, Katja Sockel1, Christian Thiede1, Martin Bornhäuser1, Gerhard Ehninger1, Arjan A van de Loosdrecht2, Uwe Platzbecker3.   

Abstract

Entities:  

Keywords:  MDS; del(5q); immunophenotypic profile

Mesh：

Substances：

Year:  2014        PMID： 25425689      PMCID： PMC4349286          DOI： 10.3324/haematol.2014.115725

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Authors:  T M Westers; R Ireland; W Kern; C Alhan; J S Balleisen; P Bettelheim; K Burbury; M Cullen; J A Cutler; M G Della Porta; A M Dräger; J Feuillard; P Font; U Germing; D Haase; U Johansson; S Kordasti; M R Loken; L Malcovati; J G te Marvelde; S Matarraz; T Milne; B Moshaver; G J Mufti; K Ogata; A Orfao; A Porwit; K Psarra; S J Richards; D Subirá; V Tindell; T Vallespi; P Valent; V H J van der Velden; T M de Witte; D A Wells; F Zettl; M C Béné; A A van de Loosdrecht
Journal:  Leukemia       Date:  2012-02-06       Impact factor: 11.528

2.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Authors:  Pierre Fenaux; Aristoteles Giagounidis; Dominik Selleslag; Odile Beyne-Rauzy; Ghulam Mufti; Moshe Mittelman; Petra Muus; Peter Te Boekhorst; Guillermo Sanz; Consuelo Del Cañizo; Agnes Guerci-Bresler; Lars Nilsson; Uwe Platzbecker; Michael Lübbert; Bruno Quesnel; Mario Cazzola; Arnold Ganser; David Bowen; Brigitte Schlegelberger; Carlo Aul; Robert Knight; John Francis; Tommy Fu; Eva Hellström-Lindberg
Journal:  Blood       Date:  2011-07-13       Impact factor: 22.113

3.  Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes.

Authors:  F Xu; L Wu; Q He; Z Zhang; C Chang; X Li
Journal:  Intern Med J       Date:  2012-04       Impact factor: 2.048

4.  Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Authors:  Ramin Tehranchi; Petter S Woll; Kristina Anderson; Natalija Buza-Vidas; Takuo Mizukami; Adam J Mead; Ingbritt Astrand-Grundström; Bodil Strömbeck; Andrea Horvat; Helen Ferry; Rakesh Singh Dhanda; Robert Hast; Tobias Rydén; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Bertil Johansson; Eva Hellström-Lindberg; Alan List; Lars Nilsson; Sten Eirik W Jacobsen
Journal:  N Engl J Med       Date:  2010-09-09       Impact factor: 91.245

5.  Immunophenotypic clustering of myelodysplastic syndromes.

Authors:  Marc Maynadié; Françoise Picard; Bernard Husson; Bernard Chatelain; Yvan Cornet; Geneviève Le Roux; Lydia Campos; Alex Dromelet; Pascalle Lepelley; Hélène Jouault; Michèle Imbert; Michelle Rosenwadj; Véronique Vergé; Philippe Bissières; Martine Raphaël; Marie Christine Béné; Jean Feuillard
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

Authors:  Denise A Wells; Martin Benesch; Michael R Loken; Carlos Vallejo; David Myerson; Wendy M Leisenring; H Joachim Deeg
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

7.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors:  Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

8.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Authors:  Kiyoyuki Ogata; Matteo G Della Porta; Luca Malcovati; Cristina Picone; Norio Yokose; Akira Matsuda; Taishi Yamashita; Hideto Tamura; Junichi Tsukada; Kazuo Dan
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

9.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Authors:  A A N Giagounidis; U Germing; S Haase; B Hildebrandt; B Schlegelberger; C Schoch; L Wilkens; M Heinsch; H Willems; M Aivado; C Aul
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

10.  Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.

Authors:  U Platzbecker; F Braulke; A Kündgen; K Götze; G Bug; C Schönefeldt; K Shirneshan; C Röllig; M Bornhäuser; R Naumann; J Neesen; A Giagounidis; W-K Hofmann; G Ehninger; U Germing; D Haase; M Wermke
Journal:  Leukemia       Date:  2013-01-28       Impact factor: 11.528
View more
  5 in total

Review 1.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

2.  Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Authors:  Theresia M Westers; Eline M P Cremers; Uta Oelschlaegel; Ulrika Johansson; Peter Bettelheim; Sergio Matarraz; Alberto Orfao; Bijan Moshaver; Lisa Eidenschink Brodersen; Michael R Loken; Denise A Wells; Dolores Subirá; Matthew Cullen; Jeroen G Te Marvelde; Vincent H J van der Velden; Frank W M B Preijers; Sung-Chao Chu; Jean Feuillard; Estelle Guérin; Katherina Psarra; Anna Porwit; Leonie Saft; Robin Ireland; Timothy Milne; Marie C Béné; Birgit I Witte; Matteo G Della Porta; Wolfgang Kern; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

3.  Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.

Authors:  Carolien Duetz; Theresia M Westers; Florentien E M In 't Hout; Eline M P Cremers; Canan Alhan; Bianca Venniker-Punt; Heleen A Visser-Wisselaar; Dana A Chitu; Aniek O de Graaf; Linda Smit; Joop H Jansen; Arjan A van de Loosdrecht
Journal:  Br J Haematol       Date:  2021-03-25       Impact factor: 6.998

4.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05

5.  Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Haifa Kathrin Al-Ali; Nadja Jaekel; Christin Le Hoa Naumann; Judith Schaffrath; Achim Rau; Barbara Seliger; Claudia Wickenhauser
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.